The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Prevention of cardiovascular disease in systemic lupus erythematosus--proposed guidelines for risk factor management
Abstract
In the past 2–3 decades it has become increasingly recognized that accelerated atherosclerosis and its sequelae are a major cause of morbidity and mortality in systemic lupus erythematosus (SLE) [1]. The consequences of this include an increased risk of cerebrovascular and coronary heart disease (CHD). To date there has been no formal attempt to devise and adapt population guidelines for prevention of CHD in the context of SLE, although several ‘targets values’ have been suggested [2, 3]. Given the risk associated with SLE, it would seem important to identify potentially modifiable risk factors and introduce evidence-based guidelines that would aid clinicians in planning strategies that may help to reduce long-term cardiovascular morbidity in SLE. The aim of this review is to develop a firm rationale for risk factor management for patients with SLE, based on the approach we have initiated at the Manchester Royal Infirmary Lupus and Connective Tissue Disease Clinic. Overall, patients with SLE have 5–10 times the risk of CHD-related events compared with the background population [2–5]. In particular, Manzi et al. [4] found that women aged 35–44 yr with SLE had a 50-times greater risk of myocardial infarction (MI) relative to healthy women in the Framingham Offspring Study cohort. In attempting to determine the absolute risk of developing CHD in SLE, two recent cohort studies have addressed this issue. In an inception cohort study, Bruce et al. [6] noted that over a mean of 12.4 yr of follow-up, 13.4% developed a new CHD-related event. Similarly, Esdaile et al. [7] in two Montreal hospital cohorts found that over a mean follow-up period of 8.6 yr, 12.9% developed CHD. The 10-yr risk of CHD-related events in SLE is therefore approximately 13–15% [5, 6]. As a comparison, Haffner et al. [8] noted that patients with type II diabetes mellitus had a 20.2% risk of CHD over 7 yr of follow-up, a risk not dissimilar to that observed in non-diabetic subjects with pre-existing CHD (18.8%). As such, type II diabetes mellitus is now classified, by the Adult Treatment Panel III Guidelines (ATP III), as a CHD-equivalent condition for the purposes of CHD prevention [9]. Clearly these studies are not directly comparable and there are several important points to note regarding SLE. First, in contrast to CHD and type II diabetes mellitus, most patients with SLE are female. Women start with a much lower baseline risk of CHD [10]. Secondly, the mean ages of cohort entry in these two SLE studies were 35 and 39 yr, respectively [6, 7], compared with 58 and 56 yr, respectively, for the type II diabetes mellitus and CHD cohorts [8]. Since increasing age is associated with CHD risk in SLE [6, 7], it is highly likely that as patients with SLE get older, the incidence rate of new CHD events may continue to increase. As such, a 13–15% 10-yr risk in a predominantly young female SLE population argues strongly for considering SLE also to be a CHD-equivalent condition. It is this approach that forms the rationale behind the individual guidelines we propose. The reason for this increased risk of CHD is likely to be multifactorial. Established risk factors are important, but do not, however, fully explain the increased risk of CHD in SLE. Several studies of prevalent clinical or subclinical atherosclerotic disease have reported that factors such as hypercholesterolaemia, hypertension and obesity increase the risk of CHD. In a single centre cohort study, Bruce et al. [6] noted that of patients who had consistently elevated total cholesterol (>5.2 mmol/l), 26% developed new CHD events over a 12-yr follow-up period. Serum cholesterol independently predicted the risk of CHD in this cohort [6]. Similarly, in a study of carotid plaque development in a cohort of women with SLE, Manzi et al. [11] found that increasing age, hypertension and increased low-density lipoprotein (LDL) cholesterol were all significant predictors of plaque development. However, Rahman et al. [12] found that at the time of their coronary event, patients with SLE have on average one less conventional risk factor compared with a control cohort of patients with accelerated atherosclerosis, but without SLE. Esdaile et al. [7] also found that after adjusting for the baseline risk of CHD estimated using the predictive Framingham risk factor estimate, patients with SLE still had a 7- to 10-fold increased risk of CHD and stroke. Additional metabolic, inflammatory and immunological factors as well as therapy with agents such as corticosteroids are therefore also likely to be of relevance. In particular, renal impairment and proteinuria are likely to have an adverse effect on cardiovascular risk in this population [2]. Furthermore, there is emerging evidence that additional factors such as endothelial dysfunction may also be more prevalent in SLE [13, 14] and recently, reduced paroxonase activity has been noted in SLE [15]. This may increase lipid peroxidation and further enhance atheroge
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
The management of thrombosis in the antiphospholipid-antibody syndrome
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321504 · Cited by 1,450
Cited by
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751
D'Cruz, D. P., Khamashta, M. A., & Hughes, G. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60279-7 · Cited by 992
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000624 · Cited by 907
Metadata
- Authors
- Wajed, J.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-01-01
- Volume
- 43
- Issue
- 1
- Pages
- 7-12
- ISSN
- 0263-7103 (ISSN-L)
- 1460-2172
- OpenAlex
- W2119071155
- Cited by
- 169
- References
- 3
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevention of cardiovascular disease in systemic lupus erythematosus--proposed guidelines for risk factor management. https://app.cochat.ai/papers/10.1093/rheumatology/keg436
- The paper
- Wajed, J. (2004). Prevention of cardiovascular disease in systemic lupus erythematosus--proposed guidelines for risk factor management. Rheumatology. https://doi.org/10.1093/rheumatology/keg436
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.